Prognostic utility of β-tubulin isotype III and correlations with other molecular and clinicopathological variables in patients with early breast cancer: A translational Hellenic Cooperative Oncology Group (HeCOG) study

Breast Cancer Research and Treatment

Volumn 127, Issue 1, 2011, Pages 179-193

  Pentheroudakis, George ^a   Batistatou, Anna ^a   Kalogeras, Konstantine T ^b,c   Kronenwett, Ralf ^d,h   Wirtz, Ralph M ^d,i   Bournakis, Evangelos ^e   Eleftheraki, Anastasia G ^c   Pectasides, Dimitrios ^e   Bobos, Mattheos ^b   Papaspirou, Irini ^f   Kamina, Sevasti ^a   Gogas, Helen ^e   Koutras, Angelos K ^g   Pavlidis, Nicholas ^a   Fountzilas, George ^b  

^a UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^c Hellenic Cooperative Oncology Group   (Greece)

^d SIEMENS AG   (Germany)

^e UNIVERSITY OF ATHENS   (Greece)

^f ALEXANDRA HOSPITAL   (Greece)

^g UNIVERSITY HOSPITAL OF PATRAS   (Greece)

^h Sividon Diagnostics GmbH   (Germany)

ⁱ STRATIFYER Molecular Pathology GmbH   (Germany)

Author keywords

tubulin isotype III; Adjuvant chemotherapy; Breast cancer; Prognostic predictive factors

Indexed keywords

BETA TUBULIN; BETA TUBULIN III; CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; FLUOROURACIL; GRANULOCYTE COLONY STIMULATING FACTOR; MESSENGER RNA; METHOTREXATE; PACLITAXEL; PROGESTERONE RECEPTOR; TAMOXIFEN; TAU PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; AXILLARY LYMPH NODE; BETA TUBULIN III GENE; BREAST CANCER; CANCER GRADING; CANCER PATIENT; CANCER STAGING; CANCER TISSUE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG EFFICACY; EARLY CANCER; FEMALE; FOLLOW UP; GENE EXPRESSION; GENETIC TRANSCRIPTION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MASTECTOMY; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PARTIAL MASTECTOMY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSLATIONAL RESEARCH; TUMOR GENE;

ADULT; AGED; BREAST NEOPLASMS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RETROSPECTIVE STUDIES; RNA, MESSENGER; SURVIVAL ANALYSIS; TUBULIN; YOUNG ADULT;

EID: 79954644097     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-011-1427-0     Document Type: Article

References (40)

1. EBCTC Group 2005 Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival:an overview of the randomised trials Lancet 365 1687 1717 10.1016/S0140-6736(05)66544-0 (Pubitemid 40719106)
2. M Trudeau F Charbonneau K Gelmon, et al. 2005 Selection of adjuvant chemotherapy for treatment of node-positive breast cancer Lancet Oncol 6 886 898 16257797 10.1016/S1470-2045(05)70424-1 1:CAS:528:DC%2BD2MXhtFOmsb%2FI (Pubitemid 41614801)
3. P Bedard A Leo M Piccart-Gebhart 2010 Taxanes: optimizing adjuvant chemotherapy for early-stage breast cancer Nat Rev Clin Oncol 7 22 36 19997076 10.1038/nrclinonc.2009.186 1:CAS:528:DC%2BD1MXhs1SqsLfL
4. KMR Bhat V Setaluri 2007 Microtubule-associated proteins as targets in cancer chemotherapy Clin Cancer Res 13 2849 2854 17504982 10.1158/1078-0432.CCR- 06-3040 1:CAS:528:DC%2BD2sXlt1Krsrw%3D (Pubitemid 46849557)
5. F Mollinedo C Gajate 2003 Microtubules, microtubule-interfering agents and apoptosis Apoptosis 8 413 450 12975575 10.1023/A:1025513106330 1:CAS:528:DC%2BD3sXmvVOmur4%3D (Pubitemid 37247987)
6. M Kavallaris 2010 Microtubules and resistance to tubulin-binding agents Nat Rev Cancer 10 194 204 20147901 10.1038/nrc2803 1:CAS:528: DC%2BC3cXhvVKrtbg%3D
7. G Fountzilas D Skarlos U Dafni H Gogas E Briasoulis, et al. 2005 Postoperative dose-dense sequential chemotherapy with epirubicin, followed byCMFwith or without paclitaxel, in patients with high-risk operable breast cancer: a randomised phase III study conducted by the Hellenic Cooperative Oncology Group Ann Oncol 16 1762 1771 16148021 10.1093/annonc/mdi366 1:STN:280:DC%2BD2MrlvFGlsw%3D%3D (Pubitemid 41631238)
8. K Bohmann G Hennig U Rogel C Poremba BM Mueller P Fritz S Stoerkel K-L Schaefer 2009 RNA extraction from archival formalin-fixed paraffin-embedded tissue: a comparison of manual, semiautomated, and fully automated purification methods Clin Chem 55 1719 1727 19617290 10.1373/clinchem.2008.122572 1:CAS:528:DC%2BD1MXhtVynt77E
9. BM Mueller R Kronenwett G Hennig H Euting K Weber, et al. 2011 Quantitative determination of estrogen receptor, progesterone receptor and HER2 mRNA in formalin-fixed paraffin-embedded tissue-a new option for predictive biomarker assessment in breast cancer Diagn Mol Pathol 20 1 10 10.1097/PDM.0b013e3181e3630c 1:CAS:528:DC%2BC3MXitVOjsrg%3D
10. ME Hammond DF Hayes M Dowsett DC Allred KL Hagerty S Badve, et al. 2010 American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer J Clin Oncol 28 2784 2795 20404251 10.1200/JCO.2009.25.6529
11. AC Wolff ME Hammond JN Schwartz KL Hagerty DC Allred RJ Cote, et al. 2007 American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer Arch Pathol Lab Med 131 18 43 19548375 1:CAS:528: DC%2BD2sXhsVOmu74%3D (Pubitemid 46174133)
12. L Pusztai J-H Jeong Y Gong JS Ross C Kim S Paik, et al. 2009 Evaluation of microtubule-associated protein-tau expression as a prognostic and predictive marker in the NSABP-B 28 randomized clinical trial J Clin Oncol 27 4287 4292 19667268 10.1200/JCO.2008.21.6887 1:CAS:528:DC%2BD1MXht1WisbjJ
13. G Pentheroudakis K Kalogeras R Wirtz I Grimani G Zografos H Gogas, et al. 2009 Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial Breast Cancer Res Treat 116 131 143 18668363 10.1007/s10549-008-0144-9 1:CAS:528:DC%2BD1MXntFaktro%3D
14. TL Hudis 2007 Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system J Clin Oncol 25 2127 2132 17513820 10.1200/JCO.2006.10.3523 (Pubitemid 46972801)
15. LM McShane DG Altman W Sauerbrei, et al. 2005 Reporting recommendations for tumor marker prognostic studies J Clin Oncol 23 9067 9072 16172462 10.1200/JCO.2004.01.0454
16. MA Jordan L Wilson 2004 Microtubules as a target for anticancer drugs Nat Rev Cancer 4 253 265 15057285 10.1038/nrc1317 1:CAS:528:DC%2BD2cXis1Gmt74%3D (Pubitemid 38525281)
17. DW Cleveland KF Sullivan 1985 Molecular biology and genetics of tubulin Annu Rev Biochem 54 331 365 3896122 10.1146/annurev.bi.54.070185.001555 1:STN:280:DyaL2M3nsl2qsw%3D%3D (Pubitemid 15073650)
18. MA Lopata DW Cleveland 1987 In vivo microtubules are copolymers of available h-tubulin isotypes: localization of each of six vertebrate h-tubulin isotypes using polyclonal antibodies elicited by synthetic peptide antigens J Cell Biol 105 1707 1720 3312237 10.1083/jcb.105.4.1707 1:CAS:528: DyaL1cXovFyluw%3D%3D
19. L Cicchillitti R Penci M Di Michele F Fillipetti D Rotilio M Benedetta Donati, et al. 2008 Proteomic characterisation of cytoskeletal and mitochondrial class III b-tubulin Mol Cancer Ther 7 2070 2079 18645017 10.1158/1535-7163.MCT- 07-2370 1:CAS:528:DC%2BD1cXoslCgu70%3D
20. GA Orr P Verdier-Pinard H McDaid SB Horwitz 2003 Mechanisms of taxol resistance related to microtubules Oncogene 22 7280 7295 14576838 10.1038/sj.onc.1206934 1:CAS:528:DC%2BD3sXotlajtbc%3D (Pubitemid 37487160)
21. S Mozzetti C Ferlini P Concolino F Fillippetti G Raspaglio S Prislei, et al. 2005 Class III b-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients Clin Cancer Res 11 298 305 15671559 1:CAS:528:DC%2BD2MXhtVegtrg%3D (Pubitemid 40075808)
22. S Hasegawa Y Miyoshi C Egawa, et al. 2003 Prediction of response to docetaxel by quantitative analysis of class I and III beta-tubulin isotype mRNA expression in human breast cancers Clin Cancer Res 9 2992 2997 12912947 1:CAS:528:DC%2BD3sXmtF2hsrs%3D (Pubitemid 36993258)
23. M Magnani F Ortuso S Soro S Alcaro A Tramontano M Botta 2006 The beta/beta III tubulin isoforms and their complexes with antimitotic agents: Docking and molecular dynamics studies FEBS J 273 3301 3310 16803461 10.1111/j.1742-4658.2006.05340.x 1:CAS:528:DC%2BD28Xot1Gjs74%3D (Pubitemid 43990933)
24. P Seve C Dumontet 2008 Is class III b-tubulin a predictive factor in patients receiving tubulin-binding agents? Oncology 9 168 175 18237851 1:CAS:528:DC%2BD1cXhsVOmsr8%3D (Pubitemid 351150128)
25. P Seve R Lai K Ding, et al. 2007 Class III beta tubulin expression and benefit from adjuvant cisplatin/vinorelbine chemotherapy in operable non-small cell lung cancer. Analysis of NCIC BR.10 Clin Cancer Res 13 994 999 17289895 10.1158/1078-0432.CCR-06-1503 1:CAS:528:DC%2BD2sXhsVyrsbs%3D (Pubitemid 46340378)
26. C Dumontet M Krajewska I Treilleux JR Mackey M Martin M Rupin, et al. 2010 BCIRG 001 molecular analysis: prognostic factors in node-positive breast cancer patients receiving adjuvant chemotherapy Clin Cancer Res 16 3988 3997 20576719 10.1158/1078-0432.CCR-10-0079 1:CAS:528:DC%2BC3cXpsVCitr0%3D
27. K Dennis M Ulttenbogaard A Chiaramello SA Moody 2002 Cloning and characterisation of 5-flanking region of the rat neuron-specific class III beta-tubulin gene Gene 294 269 277 12234689 10.1016/S0378-1119(02)00801-6 1:CAS:528:DC%2BD38XmvF2qtL4%3D (Pubitemid 35291035)
28. G Raspaglio F Filipetti S Prislei, et al. 2008 Hypoxia induces Class III beta-tubulin gene expression by HIF1a binding to its 3-flanking region Gene 409 100 108 18178340 10.1016/j.gene.2007.11.015 1:CAS:528:DC%2BD1cXnsl2nug%3D%3D
29. PP Gan E Pasquier M Kavallaris 2007 Class III b-tubulin mediates sensitivity to chemotherapeutic drugs in non small cell lung cancer Cancer Res 67 9356 9363 17909044 10.1158/0008-5472.CAN-07-0509 1:CAS:528:DC%2BD2sXhtFSnurrN (Pubitemid 47535925)
30. LW Loo DI Grove EM Williams CL Neal LA Cousens, et al. 2004 Array comparative genomic hybridization analysis of genomic alterations in breast cancer subtypes Cancer Res 64 23 8541 8549 15574760 10.1158/0008-5472.CAN-04- 1992 1:CAS:528:DC%2BD2cXhtVCjs7zK (Pubitemid 39552066)
31. GP Kaur DE Reddy DB Zimonjic JK de Riel RS Athwal 2005 Functional identification of a BAC clone from 16q24 carrying a senescence gene SEN16 for breast cancer cells Oncogene 24 1 47 54 15558027 10.1038/sj.onc.1208175 1:CAS:528:DC%2BD2MXptVCl (Pubitemid 40143864)
32. SF Chin Y Wang NP Thorne AE Teschendorff SE Pinder M Vias, et al. 2007 Using array-comparative genomic hybridization to define molecular portraits of primary breast cancers Oncogene 26 13 1959 1970 17001317 10.1038/sj.onc.1209985 1:CAS:528:DC%2BD2sXjtlWgt78%3D (Pubitemid 46474632)
33. PS Mongroo AK Rustgi 2010 The role of the miR-200 family in epithelial-mesenchymal transition Cancer Biol Ther 10 3 219 222 20592490 10.4161/cbt.10.3.12548 1:CAS:528:DC%2BC3cXhsFKntLbJ
34. NS Goldstein M Ferkowicz E Odish, et al. 2003 Minimum formalin fixation time for consistent estrogen receptor immunocytochemical staining of invasive breast carcinoma Am J Clin Pathol 120 86 92 12866377 10.1309/QPHDRB00QXGMUQ9N (Pubitemid 37046374)
35. A Rhodes 2003 Quality assurance in immunohistochemistry Am J Surg Pathol 27 1284 1285 12960815
36. KV Morris 2008 RNA-mediated transcriptional gene silencing in human cells Curr Top Microbiol Immunol 320 211 224 18268846 10.1007/978-3-540-75157-1-10 1:CAS:528:DC%2BD1cXjtVOmu74%3D
37. M Ravo M Mutarelli L Ferraro OM Grober O Paris, et al. 2008 Quantitative expression profiling of highly degraded RNA from formalin-fixed paraffin-embedded breast tumour biopsies by oligonucleotide microarrays Lab Invest 88 430 440 18305565 10.1038/labinvest.2008.11 1:CAS:528: DC%2BD1cXjs1alu7c%3D (Pubitemid 351432771)
38. J Yasuda Y Hayashizaki 2008 The RNA continent Adv Cancer Res 99 77 112 18037407 10.1016/S0065-230X(07)99003-X 1:CAS:528:DC%2BD1cXitlGqurw%3D (Pubitemid 350137253)
39. R Rouzier R Rajan P Wagner KR Hess DL Gold, et al. 2005 Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer PNAS 102 8315 8320 15914550 10.1073/pnas.0408974102 1:CAS:528: DC%2BD2MXlsV2mtLc%3D (Pubitemid 40800086)
40. F Andre C Hatzis K Anderson S Sotiriou C Mazouni, et al. 2007 Microtubule-associated protein tau is a bifunctional predictor of endocrine sensitivity and chemotherapy resistance in estrogen-receptor positive breast cancer Clin Cancer Res 13 2061 2067 17404087 10.1158/1078-0432.CCR-06-2078 1:CAS:528:DC%2BD2sXjs12rtrY%3D (Pubitemid 46649873)